# Pharmacologic Response and Safety of Inhaled Insulin in Type 1 Diabetes

> **NCT02713841** · PHASE1,PHASE2 · COMPLETED · sponsor: **Dance Biopharm Inc.** · enrollment: 12 (actual)

## Conditions studied

- Type 1 Diabetes Mellitus

## Interventions

- **DRUG:** inhaled human insulin (INH)
- **DRUG:** sc insulin lispro (LIS)

## Key facts

- **NCT ID:** NCT02713841
- **Lead sponsor:** Dance Biopharm Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-05
- **Primary completion:** 2013-07
- **Final completion:** 2013-07
- **Target enrollment:** 12 (ACTUAL)
- **Last updated:** 2016-03-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02713841

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02713841, "Pharmacologic Response and Safety of Inhaled Insulin in Type 1 Diabetes". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT02713841. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*